Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | PRKCB | P05771 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6842068 | 0.78 | MAPK13 (0.46) | GSK3BMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL992016 | 0.74 | ALDH1A1 (0.45) | GSK3BMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10697862 | 0.72 | MAPT (0.51) | GSK3BMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5161058 | 0.72 | MAPT (0.64) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL755665 | 0.72 | MAPT (0.64) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22144431 | 0.71 | NAMPT (0.41) | — | |
| SCHEMBL8587478 | 0.71 | KMT2A (0.46) | MAPTKMT2ASMN1; SMN2ALDH1A1TDP1 | |
| Diphenylamine SCHEMBL28244137 | 0.70 | HSD17B10 (0.57) | GSK3BMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5987355 | 0.69 | — | — | |
| SCHEMBL3762747 | 0.69 | ALDH1A1 (0.47) | GSK3BMAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306045-A1 | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-10 | — | — | US | claimed |
| WO-2007075911-A2 | INHIBITION OF GLYCOGEN SYNTHASE KINASE AND METHODS OF TREATING AUTOIMMUNE OR IMMUNE INFLAMMATORY DISEASE | YALE UNIVERSITY (US) | 2007-07-05 | — | — | WO | claimed |
| CN-1030353-C | Nonlinear optical materials | DU PONT (US) | 1995-11-22 | — | — | CN | claimed |
| EP-0257433-B1 | Method for the preparation of quinoline-2,3-dicarboxylic acid | AMERICAN CYANAMID CO (US) | 1994-03-23 | — | — | EP | claimed |
| CN-1059344-A | Nonlinear optical material | DU PONT (US) | 1992-03-11 | — | — | CN | claimed |
| US-20250108070-A1 | METHOD FOR REPROGRAMMING CD8+ T CELLS TO ENHANCE THEIR THERAPEUTIC POTENTIAL AND APPLICATIONS THEREOF | INSTITUT PASTEUR (FR) | 2025-04-03 | — | — | US | disclosed |
| WO-2024086347-A1 | METHODS OF DESIGING MOLECULAR GLUE DEGRADERS | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11932640-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | King Faisal University (SA) | 2024-03-19 | — | — | US | disclosed |
| US-11807639-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | King Faisal University (SA) | 2023-11-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20220288151-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES | CARMEL HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2022-09-15 | — | — | US | disclosed |
| EP-4010020-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES | Carmel-Haifa University Economic Corporation Ltd. (IL) | 2022-06-15 | — | — | EP | disclosed |
| WO-2007016485-A2 | USE OF A GSK-3 INHIBITOR TO MAINTAIN POTENCY OF CULTURED CELLS | ATHERSYS, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006083937-A2 | AGENTS AND METHODS RELATED TO REDUCING RESISTANCE TO APOPTOSIS-INDUCING DEATH RECEPTOR AGONISTS | THE UAB RESEARCH FOUNDATION (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-1995018801-A1 | BENZIMIDAZOLYL QUINOLINE-3-CARBOXYLATE DERIVATIVES, INTERMEDIATES THERETO, AND THEIR USE AS HERBICIDES | RHONE-POULENC AGRICULTURE LTD. (GB) | 1995-07-13 | — | — | WO | disclosed |
| EP-0257433-B1 | Method for the preparation of quinoline-2,3-dicarboxylic acid | AMERICAN CYANAMID CO (US) | 1994-03-23 | — | — | EP | disclosed |
| US-4757146-A | Method for the preparation of quinoline-2,3-dicarboxylic acid | AMERICAN CYANAMID COMPANY (US) | 1988-07-12 | — | — | US | disclosed |
| EP-0257433-A2 | Method for the preparation of quinoline-2,3-dicarboxylic acid | AMERICAN CYANAMID COMPANY (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4353734-A | PRE- AND POSTEMERGENCE | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA R.T. (HU) | 1982-10-12 | — | — | US | disclosed |
| US-4057432-A | PHOTOGRAPHIC COUPLERS | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JA) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306045-A1 | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease | GSK3B, GSK3A, GSKIP | GSK3B 1/4885MAPT 1196/4885MEN1 4048/4885 |
| US-20250108070-A1 | METHOD FOR REPROGRAMMING CD8+ T CELLS TO ENHANCE THEIR THERAPEUTIC POTENTIAL AND APPLICATIONS THEREOF | ICOS, CD4, NFATC1 | GSK3B 1583/4885MAPT 3028/4885MEN1 4048/4885 |
| US-11932640-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | POLB, POLA1, POLR2B | GSK3B 2136/4885MAPT 3738/4885MEN1 4714/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | GSK3B 1054/4885MAPT 3822/4885MEN1 562/4885 |
| US-11807639-B1 | Pyrrolo[3,4-b]quinoline compounds as antibacterial agents | POLB, TOP2A, POLI | GSK3B 2010/4885MAPT 3231/4885MEN1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.